Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group
about
Current status of biomarker research in neurologyThe clinical potential of etrolizumab in ulcerative colitis: hypes and hopesNatalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent RegistryDrug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases.Use of natalizumab in multiple sclerosis: current perspectives.High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.Natalizumab in Multiple Sclerosis: Long-Term Management."Cure" for multiple sclerosis (MS)-Evolving views of therapy goals in patients on different stages of the disease: A pilot study in a cohort of Polish MS patientsDesign of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.Multiple functional therapeutic effects of TnP: A small stable synthetic peptide derived from fish venom in a mouse model of multiple sclerosis.Quantification of γδ T cells and HLA-DR+ NK cells does not predict emergence of new contrast enhancing lesions in MS patients suspending natalizumab treatment.MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple SclerosisThe majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing.Some recent advances in multiple sclerosis.Unintended Immunological Consequences of Biologic Therapy.Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.Imaging Markers for Monitoring Disease Activity in Multiple Sclerosis.Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases.Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system.Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients.Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus.Progressive Multifocal Leukoencephalopathy and Monoclonal Antibodies: A Review.Multidisciplinary Rehabilitation is Efficacious and Induces Neural Plasticity in Multiple Sclerosis even when Complicated by Progressive Multifocal Leukoencephalopathy.Posterior fossa progressive multifocal leukoencephalopathy: first presentation of an unknown autoimmune disease.Systematic review of the published data on the worldwide prevalence of John Cunningham virus in patients with multiple sclerosis and neuromyelitis optica.ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphatAssociation of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.Asymptomatic progressive multifocal leukoencephalopathy: a case report and review of the literature.
P2860
Q26744505-3C6F2B13-BBA7-4B85-B953-AED1A49278FDQ26745725-418FA8FA-D506-442D-8750-2F581ADD0C6AQ28555138-A4CF3A15-531C-4565-856D-9AC3FB6F8710Q30815289-3430B8AB-A1BD-4D68-9B1D-88E274BCCA72Q31114633-9D970F84-9202-4ADA-AE95-F204A411E43CQ33736193-FF449E5B-4C0A-40FA-8588-D13B7506EC05Q33754882-9B065273-21EE-4FEF-8A04-C6567DB3B0EBQ33810097-A29C14CD-901D-45BC-BC2F-B5E6E60D2E96Q36073992-FD93F246-AF56-4D20-AEAA-261262C97617Q36290143-5BA21F32-A3DE-478C-80D4-CF7106A2DB58Q36394016-259699AB-A7A6-4053-9290-7CAC0540BF63Q36400004-D3035CBB-F1F0-41D8-BA01-ED502A70C194Q36484448-32D74969-475B-4BC2-B1C5-84B66FCD2C02Q38796218-D915407F-1899-4149-82DB-7B8EB9DB8AEEQ38817473-807BBF25-4A14-469E-9A49-D77BE1069D59Q38871098-FAD9BEE5-242D-4950-AB83-8BFF7EDAEEF3Q38984981-9BF41FF4-A770-4B3B-AB97-3E3F54B0FD6EQ39211049-F8ED93F7-593E-40DB-8C0C-5522C503C8CCQ39247449-2F7B6555-A629-423F-AEB6-4378F28E8F7CQ39269762-B0EA4366-AD7F-43D5-8B8D-BC8F5420B62EQ39325788-0305A0AA-808E-454B-914A-7E62060484F6Q39705818-BA31B643-21C9-4C36-A64D-1BD1040AFAE0Q39711019-D8D218C0-69AD-405F-9289-1C6EE08F7F38Q40077487-12F34E92-B46A-401A-BB81-32327578CD0CQ40666987-7AE0822F-9769-4572-95D0-A293EA55D544Q41924854-81107F21-6CB1-49C4-8803-BCB0EFC6DE05Q42363059-981ACF56-D4C7-4884-917F-A97D77353A0CQ42650343-E2527473-D2C1-4BC2-9446-210BFCDF84FBQ47548881-5753BDBA-683E-4870-B296-F168B8612A5BQ50086043-65DAAACA-AACC-494D-B6FE-5C244E1331BCQ52659119-A55F4773-DFF7-4099-8B7D-655A3295F1B9Q55516242-C2AD3B25-981D-4888-894A-FCC7A9A19777
P2860
Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group
description
2016 nî lūn-bûn
@nan
2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Stratification and monitoring ...... endations from an expert group
@ast
Stratification and monitoring ...... endations from an expert group
@en
Stratification and monitoring ...... endations from an expert group
@nl
type
label
Stratification and monitoring ...... endations from an expert group
@ast
Stratification and monitoring ...... endations from an expert group
@en
Stratification and monitoring ...... endations from an expert group
@nl
prefLabel
Stratification and monitoring ...... endations from an expert group
@ast
Stratification and monitoring ...... endations from an expert group
@en
Stratification and monitoring ...... endations from an expert group
@nl
P2093
P2860
P921
P3181
P356
P1476
Stratification and monitoring ...... endations from an expert group
@en
P2093
C McGuigan
G Mazibrada
J Guadagno
O R Pearson
P Molyneux
P2860
P304
P3181
P356
10.1136/JNNP-2015-311100
P407
P5008
P577
2016-02-01T00:00:00Z